LJL. Fredrik Jarskog

L. Fredrik Jarskog

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


L. Fredrik Jarskog has a total of 112 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Childhood trauma in people with psychosis: implications for emotion awareness and regulation

    by S. A. Miller, L. H. Ospina, B. Ozomaro, J. S. Ballon, J. P. McEvoy, L. F. Jarskog, T. S. Stroup, D. Kimhy

    Emotion awareness and regulation (EAR) are critical for effective social functioning. Individuals with psychosis display ineffective EAR, contributing substantially to poor functional outcomes. Reports in non-clinical and other clinical populations have linked childhood trauma to poor EAR. However, limited information is available about the developmental origins of EAR in people with psychosis. We investigated the links between childhood trauma and EAR in 90 individuals with psychosis. Ninety-one percent of the participants reported childhood trauma: 40.0% emotional abuse, 35.6% physical abuse, 21.1% sexual abuse, 46.7% emotional neglect, and 40.0% physical neglect. Higher degree of childhood trauma predicted greater difficulties in identifying and describing feelings in adulthood. Specifically, emotional abuse significantly predicted difficulties identifying feelings (β=0.48; 22% of the variance) and describing feelings (β=0.38; 23% of the variance). Notably, being female was associated with fewer difficulties describing feelings. Physical abuse, sexual abuse, and emotional and physical neglect were not significant predictors of EAR. For emotional regulation, models predicting use of suppression and cognitive reappraisal yielded trending results and no significance, respectively. The findings highlight the critical role of childhood trauma in shaping EAR in individuals with psychosis. The authors discuss the findings' clinical, functional, and therapeutic implications.


  • Open Access

    Telehealth-Based vs In-Person Aerobic Exercise in Individuals With Schizophrenia: Comparative Analysis of Feasibility, Safety, and Efficacy

    by David Kimhy, Luz H Ospina, Melanie Wall, Daniel M Alschuler, Lars F Jarskog, Jacob S Ballon, Joseph McEvoy, Matthew N Bartels, Richard Buchsbaum, Marianne Goodman, et al.

    Background: Aerobic exercise (AE) training has been shown to enhance aerobic fitness in people with schizophrenia. Traditionally, such training has been administered in person at gyms or other communal exercise spaces. However, following the advent of the COVID-19 pandemic, many clinics transitioned their services to telehealth-based delivery. Yet, at present, there is scarce information about the feasibility, safety, and efficacy of telehealth-based AE in this population. Objective: To examine the feasibility, safety, and efficacy of trainer-led, at-home, telehealth-based AE in individuals with schizophrenia. Methods: We analyzed data from the AE arm (n=37) of a single-blind, randomized clinical trial examining the impact of a 12-week AE intervention in people with schizophrenia. Following the onset of the COVID-19 pandemic, the AE trial intervention transitioned from in-person to at-home, telehealth-based delivery of AE, with the training frequency and duration remaining identical. We compared the feasibility, safety, and efficacy of the delivery of trainer-led AE training among participants undergoing in-person (pre–COVID-19; n=23) versus at-home telehealth AE (post–COVID-19; n=14). Results: The telehealth and in-person participants attended a similar number of exercise sessions across the 12-week interventions (26.8, SD 10.2 vs 26.1, SD 9.7, respectively; P=.84) and had similar number of weeks with at least 1 exercise session (10.4, SD 3.4 vs 10.6, SD 3.1, respectively; P=.79). The telehealth-based AE was associated with a significantly lower drop-out rate (telehealth: 0/14, 0%; in-person: 7/23, 30.4%; P=.04). There were no significant group differences in total time spent exercising (telehealth: 1246, SD 686 min; in-person: 1494, SD 580 min; P=.28); however, over the 12-week intervention, the telehealth group had a significantly lower proportion of session-time exercising at or above target intensity (telehealth: 33.3%, SD 21.4%; in-person: 63.5%, SD 16.3%; P<.001). There were no AE-related serious adverse events associated with either AE delivery format. Similarly, there were no significant differences in the percentage of participants experiencing minor or moderate adverse events, such as muscle soreness, joint pain, blisters, or dyspnea (telehealth: 3/14, 21%; in-person: 5/19, 26%; P>.99) or in the percentage of weeks per participant with at least 1 exercise-related adverse event (telehealth: 31%, SD 33%; in-person: 40%, SD 33%; P=.44). There were no significant differences between the telehealth versus in-person groups regarding changes in aerobic fitness as indexed by maximum oxygen consumption (VO2max; P=.27). Conclusions: Our findings provide preliminary support for the delivery of telehealth-based AE for individuals with schizophrenia. Our results indicate that in-home telehealth-based AE is feasible and safe in this population, although when available, in-person AE appears preferable given the opportunity for social interactions and the higher intensity of exercises. We discuss the findings’ clinical implications, specifically within the context of the COVID-19 pandemic, as well as review potential challenges for the implementation of telehealth-based AE among people with schizophrenia.


  • Medications for Psychosis: Dopamine Blockers and Dopamine Partial Agonists (Antipsychotics)

    by Hiroyuki Uchida, Euitae Kim, L. Fredrik Jarskog, W. Wolfgang Fleischhacker, Gary Remington, Jeffrey A. Lieberman

  • Medications for Psychosis: Dopamine Blockers and Dopamine Partial Agonists (Antipsychotics)

    by Hiroyuki Uchida, Euitae Kim, L. Fredrik Jarskog, W. Wolfgang Fleischhacker, Gary Remington, Jeffrey A. Lieberman


  • Systematic Quality Improvement and Metabolic Monitoring for Individuals Taking Antipsychotic Drugs

    by Takahiro Soda, Jennifer Richards, Bradley N. Gaynes, Michelle Cueva, Jeffrey Laux, Christine McClain, Rachel Frische, Lisa K. Lindquist, Gary S. Cuddeback, L. Fredrik Jarskog

    Objective: The authors sought to increase the rate of cardiometabolic monitoring for patients receiving antipsychotic drugs in an academic outpatient psychiatric clinic serving people with serious mental illness. Methods: Using a prospective quasi-experimental, interrupted time-series design with data from the electronic health record (EHR), the authors determined metabolic monitoring rates before, during, and after implementation of prespecified quality improvement (QI) measures between August 2016 and July 2017. QI measures included a combination of provider, patient, and staff education; systematic barrier reduction; and an EHR-based reminder system. Results: After 1 year of QI implementation, the rate of metabolic monitoring had increased from 33% to 49% (p<0.01) for the primary outcome measure (hemoglobin A1C and lipid panel). This increased monitoring rate was sustained for 27 months beyond the end of the QI intervention. More than 75% of providers did not find the QI reminders burdensome. Conclusions: Significant improvement in the rate of metabolic monitoring for people taking antipsychotic drugs can be achieved with little added burden on providers. Future research needs to assess the full range of patient, provider, and system barriers that prevent cardiometabolic monitoring for all individuals receiving antipsychotic drugs.


  • Targeting physical health in schizophrenia: Results from the Physical Activity Can Enhance Life (PACE-Life) 24-week open trial

    by Julia Browne, Claudio Battaglini, L. Fredrik Jarskog, Paschal Sheeran, Ana M. Abrantes, Jessica McDermott, Tonya Elliott, Oscar Gonzalez, David L. Penn


  • Open Access

    A case study of the feasibility of weekly tACS for the treatment of auditory hallucinations in schizophrenia

    by Rachel B. Force, Justin Riddle, L. Fredrik Jarskog, Flavio Fröhlich


  • Open Access

    Depression and reduced emotional experience in schizophrenia: Correlations with self-reported and informant-rated everyday social functioning

    by Philip D. Harvey, Elizabeth Deckler, Mackenzie T. Jones, L. Fredrik Jarskog, David L. Penn, Amy E. Pinkham

    Negative symptoms and depression persist in one third of patients with schizophrenia. Previous studies suggested that depression has more impact on self-perceived compared to observer-rated social functions. Reduced emotional experience, a subdomain of negative symptoms, predicts social functioning deficits, although its role in self-assessment is unclear. We examined depression and reduced emotional experience and self-reports and informant ratings of social functioning and social cognitive abilities in 135 patients with schizophrenia. Discrepancies between sources were used to index the accuracy and bias in self-assessment. Less severe depression was associated with self-reports of reduced impairments in social functioning and better social cognitive abilities. Reduced emotional experience was related to informant ratings and self-reports of social functioning. Neither reduced emotional experience nor depression was correlated with discrepancies between sources, despite the bias of patients with lower depression to report that they were higher functioning and more competent. These findings suggest that patients with schizophrenia make global judgments about functioning based on current mood states. There was minimal association between the depression severity and the accuracy of self-assessment, despite positive biases associated with lower depression severity. The determinants of accuracy and bias in self-assessment requires more detailed examination and subdivision of patients based on their depression.


  • A 12-week randomized controlled trial of twice-daily intranasal oxytocin for social cognitive deficits in people with schizophrenia

    by L. Fredrik Jarskog, Cort A. Pedersen, Jacqueline L. Johnson, Robert M. Hamer, Shane W. Rau, Tonya Elliott, David L. Penn


  • Task-related fMRI responses to a nicotinic acetylcholine receptor partial agonist in schizophrenia: A randomized trial

    by Deanna M. Barch, Stephen R. Marder, Michael P. Harms, L. Fredrik Jarskog, Robert W. Buchanan, Will Cronenwett, Li-Shiun Chen, Markus Weiss, Ralph P. Maguire, Nicole Pezous, et al.